DBPR110 is a potent inhibitor of nonstructural protein 5A (NS5A), specifically targeting hepatitis C virus (HCV) replication. It demonstrates significant antiviral activity with an EC50 of 3.9 ± 0.9 pM against HCV1b replicon reporter expression, and a selectivity index exceeding 12,800,000. Additionally, DBPR110 reduces HCV2a replicon activity with an EC50 of 228.8 pM and a selectivity index of over 173,130. This compound exhibits synergistic effects when used in combination with interferon alpha (IFN-α) and other antiviral agents, suggesting its potential as a viable small molecule therapeutic for HCV treatment.
DBPR110 is a potent inhibitor of nonstructural protein 5A (NS5A), specifically targeting hepatitis C virus (HCV) replication. It demonstrates significant antiviral activity with an EC50 of 3.9 ± 0.9 pM against HCV1b replicon reporter expression, and a selectivity index exceeding 12,800,000. Additionally, DBPR110 reduces HCV2a replicon activity with an EC50 of 228.8 pM and a selectivity index of over 173,130. This compound exhibits synergistic effects when used in combination with interferon alpha (IFN-α) and other antiviral agents, suggesting its potential as a viable small molecule therapeutic for HCV treatment.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
